Review

anti human cd39 polyclonal antibody (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech anti human cd39 polyclonal antibody

The roles of CD39⁺CD8⁺ TILs in the tumor immune microenvironment. The left panel depicts CD39⁺CD8⁺ T cells with features consistent with antitumor activity, including increased TCR clonal expansion and an effector-like feature. The right panel shows that, in bladder cancer patient cohorts, CD39⁺CD8⁺ TILs are associated with clinical outcomes. In parallel, adoptive transfer experiments in a murine bladder cancer model support a functional contribution of CD39⁺CD8⁺ T cells to tumor control. Overall, the scheme highlights <t>CD39</t> as a practical biomarker to enrich tumor-reactive CD8⁺ TILs and to inform the development of cancer immunotherapy.

Anti Human Cd39 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd39+polyclonal+antibody/ENTPD1+Fusion+Protein/pmc13050436-91-11-15
Average 94 stars, based on 2 article reviews

anti human cd39 polyclonal antibody - by Bioz Stars, 2026-09

94/100 stars

Images

1) Product Images from "Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor"

Article Title: Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor

Journal: International Journal of Biological Sciences

doi: 10.7150/ijbs.130389

Figure Legend Snippet: The roles of CD39⁺CD8⁺ TILs in the tumor immune microenvironment. The left panel depicts CD39⁺CD8⁺ T cells with features consistent with antitumor activity, including increased TCR clonal expansion and an effector-like feature. The right panel shows that, in bladder cancer patient cohorts, CD39⁺CD8⁺ TILs are associated with clinical outcomes. In parallel, adoptive transfer experiments in a murine bladder cancer model support a functional contribution of CD39⁺CD8⁺ T cells to tumor control. Overall, the scheme highlights CD39 as a practical biomarker to enrich tumor-reactive CD8⁺ TILs and to inform the development of cancer immunotherapy.

Techniques Used: Activity Assay, Adoptive Transfer Assay, Functional Assay, Control, Biomarker Discovery

Clinical prognosis association and single-cell distribution of CD39 (ENTPD1). (A) Kaplan-Meier analysis of overall survival stratified by ENTPD1 expression across multiple solid tumor types in TCGA. (B) Kaplan-Meier analysis stratified by ENTPD1 expression in patients receiving immune checkpoint blockade. (C) t-SNE of integrated scRNA-seq data from 20 BLCA patients, annotated into 9 major cell types. (D) FeaturePlot of ENTPD1 expression across all cells and split by tissue origin (bladder normal vs tumor). (E) Average ENTPD1 expression across major cell types. (F) Comparison of average ENTPD1 expression between tumor and normal tissues within each major cell type. (G) t-SNE visualization of the CD8 + T cell populations from bladder tumor. (H) FeaturePlot of ENTPD1 expression across CD8⁺ T cell subsets in tumor tissue. (I) Average ENTPD1 expression across CD8⁺ T cell subsets.

Figure Legend Snippet: Clinical prognosis association and single-cell distribution of CD39 (ENTPD1). (A) Kaplan-Meier analysis of overall survival stratified by ENTPD1 expression across multiple solid tumor types in TCGA. (B) Kaplan-Meier analysis stratified by ENTPD1 expression in patients receiving immune checkpoint blockade. (C) t-SNE of integrated scRNA-seq data from 20 BLCA patients, annotated into 9 major cell types. (D) FeaturePlot of ENTPD1 expression across all cells and split by tissue origin (bladder normal vs tumor). (E) Average ENTPD1 expression across major cell types. (F) Comparison of average ENTPD1 expression between tumor and normal tissues within each major cell type. (G) t-SNE visualization of the CD8 + T cell populations from bladder tumor. (H) FeaturePlot of ENTPD1 expression across CD8⁺ T cell subsets in tumor tissue. (I) Average ENTPD1 expression across CD8⁺ T cell subsets.

Techniques Used: Single Cell, Expressing, Comparison

Figure Legend Snippet: Single-cell transcriptional profile and bulk TCR repertoire of human bladder cancer. (A) t-SNE visualization of integrated scRNA-seq data showing CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (B) Comparison of the cell ratio of major cell types in CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (C) Volcano plot shown the differentially expressed genes between CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (D) GO enrichment analysis of genes upregulated in CD39⁺CD8⁺ TILs. (E) GSEA enrichment plots of T cell function-related genes upregulated in CD39⁺CD8⁺ TILs. (F) Signature scores for tumor reactivity, tumor specificity, mutation-associated neoantigen (MANA) TIL, proliferation and virus-specific gene signatures. (G) Expression of CD39 + CD8 + TIL signature-related genes (G) Kaplan-Meier curves for overall survival stratified by CD39⁺CD8⁺ TIL signature enrichment in the TCGA-BLCA cohort (n = 424) and the IMvigor210 cohort (n = 195). (H) Tree maps of TCR clonotypes in CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (I) Relative frequencies of the top 10 most abundant TCR clonotypes. **** P < 0.0001.

Techniques Used: Single Cell, Comparison, Cell Function Assay, Mutagenesis, Virus, Expressing

Tumor-infiltrating CD39⁺CD8⁺ T cells are enriched in BLCA, display an effector-like phenotype, and associate with tumor stage and patient survival. (A) Representative double-stained immunohistochemistry (IHC) image for CD39 (brown) and CD8 (pink) in tumor tissue slice. Black arrowheads indicate CD8 + T cell, red arrowheads indicate CD39 + CD8 + T cell. Scale bar, 20 μm. (B) Quantification of CD8⁺ T cell infiltration in tumor and normal bladder tissues. (C) Quantification of CD39⁺CD8⁺ T cell infiltration in tumor and normal bladder tissues. (D) Representative flow cytometry gating of CD8 expression of CD3 + T cells and quantification of CD8⁺ T cell frequencies across tumor stages. (E) Representative flow cytometry gating of CD39 expression of CD8 + T cells and quantification of CD39 + CD8⁺ T cell frequencies across tumor stages. (F) Correlation between CD39 expression and PD-1, CD103, CD134, and CD137 expression on tumor-infiltrating CD8⁺ T cell. (G) Flow cytometric comparison of CD103, CD134, and CD137 frequencies between CD8⁺CD39⁻ and CD8⁺CD39⁺ T cells. (H) Kaplan-Meier analysis of overall survival stratified by intratumoral CD8 + T cell and CD39⁺CD8⁺ T cell infiltration in the NJDT cohort (n = 82). ** P < 0.01, **** P < 0.0001.

Figure Legend Snippet: Tumor-infiltrating CD39⁺CD8⁺ T cells are enriched in BLCA, display an effector-like phenotype, and associate with tumor stage and patient survival. (A) Representative double-stained immunohistochemistry (IHC) image for CD39 (brown) and CD8 (pink) in tumor tissue slice. Black arrowheads indicate CD8 + T cell, red arrowheads indicate CD39 + CD8 + T cell. Scale bar, 20 μm. (B) Quantification of CD8⁺ T cell infiltration in tumor and normal bladder tissues. (C) Quantification of CD39⁺CD8⁺ T cell infiltration in tumor and normal bladder tissues. (D) Representative flow cytometry gating of CD8 expression of CD3 + T cells and quantification of CD8⁺ T cell frequencies across tumor stages. (E) Representative flow cytometry gating of CD39 expression of CD8 + T cells and quantification of CD39 + CD8⁺ T cell frequencies across tumor stages. (F) Correlation between CD39 expression and PD-1, CD103, CD134, and CD137 expression on tumor-infiltrating CD8⁺ T cell. (G) Flow cytometric comparison of CD103, CD134, and CD137 frequencies between CD8⁺CD39⁻ and CD8⁺CD39⁺ T cells. (H) Kaplan-Meier analysis of overall survival stratified by intratumoral CD8 + T cell and CD39⁺CD8⁺ T cell infiltration in the NJDT cohort (n = 82). ** P < 0.01, **** P < 0.0001.

Techniques Used: Staining, Immunohistochemistry, Flow Cytometry, Expressing, Comparison

Single-cell transcriptomic profiling identifies an effector-like program in CD39⁺CD8⁺ TILs from the murine MB49 model. (A) Experimental workflow for FACS isolation of CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs from MB49 tumors followed by paired scRNA-seq and scTCR-seq. (B) t-SNE visualization of scRNA-seq data showing the distribution of CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (C) Comparison of the cell ratio of major cell types in CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (D) Volcano plot shows the differentially expressed genes between CD39 + CD8 + TILs and CD39 - CD8 + TILs. (E) GO enrichment analysis of genes upregulated in CD39⁺CD8⁺ TILs. (F) GSEA enrichment plots of T cell function-related genes upregulated in CD39⁺CD8⁺ TILs. (G) Signature scores for tumor reactivity, tumor specificity and virus-specific gene signatures. **** P < 0.0001.

Figure Legend Snippet: Single-cell transcriptomic profiling identifies an effector-like program in CD39⁺CD8⁺ TILs from the murine MB49 model. (A) Experimental workflow for FACS isolation of CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs from MB49 tumors followed by paired scRNA-seq and scTCR-seq. (B) t-SNE visualization of scRNA-seq data showing the distribution of CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (C) Comparison of the cell ratio of major cell types in CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (D) Volcano plot shows the differentially expressed genes between CD39 + CD8 + TILs and CD39 - CD8 + TILs. (E) GO enrichment analysis of genes upregulated in CD39⁺CD8⁺ TILs. (F) GSEA enrichment plots of T cell function-related genes upregulated in CD39⁺CD8⁺ TILs. (G) Signature scores for tumor reactivity, tumor specificity and virus-specific gene signatures. **** P < 0.0001.

Techniques Used: Single Cell, Isolation, Comparison, Cell Function Assay, Virus

Clonotype-resolved single-cell TCR analysis identifies tumor-reactive TCR sequence from CD39⁺CD8⁺ TILs. (A) Distribution of TCR clonotypes from MB49 tumor. (B) Stacked chart shows TCR clone-size distribution of CD39 +/- CD8 + T cells population. (C) Tree maps of TCR clonotypes in CD39 +/- CD8 + TIL population. (D) Co-expression of CD39 and N4 tetramer among CD8 + TILs in MB49-OVA tumor. (E) mRNA expression levels of Tnf , Ifng , Gzma , Gzmk , Prf1 and Nkg7 in the dominant TCR clonotype of CD39 + CD8 + TILs and the top 5 TCR clonotypes from CD39 - CD8 + TILs. (F) Scheme summarizes the activation and cytotoxicity assay of tumor reactive TCR. (G-H) Expression of CD69 on TCR-Jurkat cells after co-culture with MB49 tumor cells. (I) Viral infection efficiency of TCR-T cells. (J) Representative microscopy image after 24 hours co-culture of TCR-T cells with MB49 tumor cells. (K) Tumor cell killing by TCR-T cells in co-culture with MB49 cells. (L) TCR-Jurkat co-cultured with tumor cells of different MHC background, including CT26 (H-2K d ) or UMUC3 (HLA-A*02). (M) TCR-Jurkat co-cultured with normal renal cells. ns, P > 0.05, *** P < 0.001.

Figure Legend Snippet: Clonotype-resolved single-cell TCR analysis identifies tumor-reactive TCR sequence from CD39⁺CD8⁺ TILs. (A) Distribution of TCR clonotypes from MB49 tumor. (B) Stacked chart shows TCR clone-size distribution of CD39 +/- CD8 + T cells population. (C) Tree maps of TCR clonotypes in CD39 +/- CD8 + TIL population. (D) Co-expression of CD39 and N4 tetramer among CD8 + TILs in MB49-OVA tumor. (E) mRNA expression levels of Tnf , Ifng , Gzma , Gzmk , Prf1 and Nkg7 in the dominant TCR clonotype of CD39 + CD8 + TILs and the top 5 TCR clonotypes from CD39 - CD8 + TILs. (F) Scheme summarizes the activation and cytotoxicity assay of tumor reactive TCR. (G-H) Expression of CD69 on TCR-Jurkat cells after co-culture with MB49 tumor cells. (I) Viral infection efficiency of TCR-T cells. (J) Representative microscopy image after 24 hours co-culture of TCR-T cells with MB49 tumor cells. (K) Tumor cell killing by TCR-T cells in co-culture with MB49 cells. (L) TCR-Jurkat co-cultured with tumor cells of different MHC background, including CT26 (H-2K d ) or UMUC3 (HLA-A*02). (M) TCR-Jurkat co-cultured with normal renal cells. ns, P > 0.05, *** P < 0.001.

Techniques Used: Single Cell, Sequencing, Expressing, Activation Assay, Cytotoxicity Assay, Co-Culture Assay, Infection, Microscopy, Cell Culture

Immunohistochemistry:

Article Title: Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor
Article Snippet: .. For double IHC staining, anti-human CD8 monoclonal antibody (Proteintech, cat#66868-1-Ig) and anti-human CD39 polyclonal antibody (Proteintech, cat14211-1-AP) were used for IHC staining. ..

Staining:

Image Search Results

Journal: International Journal of Biological Sciences

Article Title: Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor

doi: 10.7150/ijbs.130389

Figure Lengend Snippet: The roles of CD39⁺CD8⁺ TILs in the tumor immune microenvironment. The left panel depicts CD39⁺CD8⁺ T cells with features consistent with antitumor activity, including increased TCR clonal expansion and an effector-like feature. The right panel shows that, in bladder cancer patient cohorts, CD39⁺CD8⁺ TILs are associated with clinical outcomes. In parallel, adoptive transfer experiments in a murine bladder cancer model support a functional contribution of CD39⁺CD8⁺ T cells to tumor control. Overall, the scheme highlights CD39 as a practical biomarker to enrich tumor-reactive CD8⁺ TILs and to inform the development of cancer immunotherapy.

Article Snippet: For double IHC staining, anti-human CD8 monoclonal antibody (Proteintech, cat#66868-1-Ig) and anti-human CD39 polyclonal antibody (Proteintech, cat#14211-1-AP) were used for IHC staining.

Techniques: Activity Assay, Adoptive Transfer Assay, Functional Assay, Control, Biomarker Discovery

Journal: International Journal of Biological Sciences

Article Title: Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor

doi: 10.7150/ijbs.130389

Figure Lengend Snippet: Clinical prognosis association and single-cell distribution of CD39 (ENTPD1). (A) Kaplan-Meier analysis of overall survival stratified by ENTPD1 expression across multiple solid tumor types in TCGA. (B) Kaplan-Meier analysis stratified by ENTPD1 expression in patients receiving immune checkpoint blockade. (C) t-SNE of integrated scRNA-seq data from 20 BLCA patients, annotated into 9 major cell types. (D) FeaturePlot of ENTPD1 expression across all cells and split by tissue origin (bladder normal vs tumor). (E) Average ENTPD1 expression across major cell types. (F) Comparison of average ENTPD1 expression between tumor and normal tissues within each major cell type. (G) t-SNE visualization of the CD8 + T cell populations from bladder tumor. (H) FeaturePlot of ENTPD1 expression across CD8⁺ T cell subsets in tumor tissue. (I) Average ENTPD1 expression across CD8⁺ T cell subsets.

Techniques: Single Cell, Expressing, Comparison

Journal: International Journal of Biological Sciences

Article Title: Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor

doi: 10.7150/ijbs.130389

Figure Lengend Snippet: Single-cell transcriptional profile and bulk TCR repertoire of human bladder cancer. (A) t-SNE visualization of integrated scRNA-seq data showing CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (B) Comparison of the cell ratio of major cell types in CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (C) Volcano plot shown the differentially expressed genes between CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (D) GO enrichment analysis of genes upregulated in CD39⁺CD8⁺ TILs. (E) GSEA enrichment plots of T cell function-related genes upregulated in CD39⁺CD8⁺ TILs. (F) Signature scores for tumor reactivity, tumor specificity, mutation-associated neoantigen (MANA) TIL, proliferation and virus-specific gene signatures. (G) Expression of CD39 + CD8 + TIL signature-related genes (G) Kaplan-Meier curves for overall survival stratified by CD39⁺CD8⁺ TIL signature enrichment in the TCGA-BLCA cohort (n = 424) and the IMvigor210 cohort (n = 195). (H) Tree maps of TCR clonotypes in CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (I) Relative frequencies of the top 10 most abundant TCR clonotypes. **** P < 0.0001.

Techniques: Single Cell, Comparison, Cell Function Assay, Mutagenesis, Virus, Expressing

Journal: International Journal of Biological Sciences

Article Title: Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor

doi: 10.7150/ijbs.130389

Figure Lengend Snippet: Tumor-infiltrating CD39⁺CD8⁺ T cells are enriched in BLCA, display an effector-like phenotype, and associate with tumor stage and patient survival. (A) Representative double-stained immunohistochemistry (IHC) image for CD39 (brown) and CD8 (pink) in tumor tissue slice. Black arrowheads indicate CD8 + T cell, red arrowheads indicate CD39 + CD8 + T cell. Scale bar, 20 μm. (B) Quantification of CD8⁺ T cell infiltration in tumor and normal bladder tissues. (C) Quantification of CD39⁺CD8⁺ T cell infiltration in tumor and normal bladder tissues. (D) Representative flow cytometry gating of CD8 expression of CD3 + T cells and quantification of CD8⁺ T cell frequencies across tumor stages. (E) Representative flow cytometry gating of CD39 expression of CD8 + T cells and quantification of CD39 + CD8⁺ T cell frequencies across tumor stages. (F) Correlation between CD39 expression and PD-1, CD103, CD134, and CD137 expression on tumor-infiltrating CD8⁺ T cell. (G) Flow cytometric comparison of CD103, CD134, and CD137 frequencies between CD8⁺CD39⁻ and CD8⁺CD39⁺ T cells. (H) Kaplan-Meier analysis of overall survival stratified by intratumoral CD8 + T cell and CD39⁺CD8⁺ T cell infiltration in the NJDT cohort (n = 82). ** P < 0.01, **** P < 0.0001.

Techniques: Staining, Immunohistochemistry, Flow Cytometry, Expressing, Comparison

Journal: International Journal of Biological Sciences

Article Title: Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor

doi: 10.7150/ijbs.130389

Figure Lengend Snippet: Single-cell transcriptomic profiling identifies an effector-like program in CD39⁺CD8⁺ TILs from the murine MB49 model. (A) Experimental workflow for FACS isolation of CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs from MB49 tumors followed by paired scRNA-seq and scTCR-seq. (B) t-SNE visualization of scRNA-seq data showing the distribution of CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (C) Comparison of the cell ratio of major cell types in CD39⁺CD8⁺ TILs and CD39⁻CD8⁺ TILs. (D) Volcano plot shows the differentially expressed genes between CD39 + CD8 + TILs and CD39 - CD8 + TILs. (E) GO enrichment analysis of genes upregulated in CD39⁺CD8⁺ TILs. (F) GSEA enrichment plots of T cell function-related genes upregulated in CD39⁺CD8⁺ TILs. (G) Signature scores for tumor reactivity, tumor specificity and virus-specific gene signatures. **** P < 0.0001.

Techniques: Single Cell, Isolation, Comparison, Cell Function Assay, Virus

Journal: International Journal of Biological Sciences

Article Title: Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor

doi: 10.7150/ijbs.130389

Figure Lengend Snippet: Clonotype-resolved single-cell TCR analysis identifies tumor-reactive TCR sequence from CD39⁺CD8⁺ TILs. (A) Distribution of TCR clonotypes from MB49 tumor. (B) Stacked chart shows TCR clone-size distribution of CD39 +/- CD8 + T cells population. (C) Tree maps of TCR clonotypes in CD39 +/- CD8 + TIL population. (D) Co-expression of CD39 and N4 tetramer among CD8 + TILs in MB49-OVA tumor. (E) mRNA expression levels of Tnf , Ifng , Gzma , Gzmk , Prf1 and Nkg7 in the dominant TCR clonotype of CD39 + CD8 + TILs and the top 5 TCR clonotypes from CD39 - CD8 + TILs. (F) Scheme summarizes the activation and cytotoxicity assay of tumor reactive TCR. (G-H) Expression of CD69 on TCR-Jurkat cells after co-culture with MB49 tumor cells. (I) Viral infection efficiency of TCR-T cells. (J) Representative microscopy image after 24 hours co-culture of TCR-T cells with MB49 tumor cells. (K) Tumor cell killing by TCR-T cells in co-culture with MB49 cells. (L) TCR-Jurkat co-cultured with tumor cells of different MHC background, including CT26 (H-2K d ) or UMUC3 (HLA-A*02). (M) TCR-Jurkat co-cultured with normal renal cells. ns, P > 0.05, *** P < 0.001.

Techniques: Single Cell, Sequencing, Expressing, Activation Assay, Cytotoxicity Assay, Co-Culture Assay, Infection, Microscopy, Cell Culture

Expression Patterns of B7-H3 and CD39 in Gastric Precancerous Lesions and Gastric Cancer Tissues. (A) Representative IHC Expression Patterns of B7-H3 and CD39 Across Different Pathological Stages (CSG, CAG, LGIN, HGIN, and GC). (B) Quantitative Analysis of Positive Expression Areas of CD39. (C) Quantitative Analysis of Positive Expression Areas of B7-H3. (D) Representative Multiplex IHC Expression Patterns of B7-H3 and CD39 Across Different Pathological Stages (CSG, CAG, LGIN, HGIN, and GC). (E) Quantitative Analysis of Multiplex IHC Expression of B7-H3 and CD39. (F) Representative Co-Localization Expression of B7-H3 and CD39 in GC. IHC Scale Bars: 50 µm; mIHC Scale Bars: 100 µm.

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Expression Patterns of B7-H3 and CD39 in Gastric Precancerous Lesions and Gastric Cancer Tissues. (A) Representative IHC Expression Patterns of B7-H3 and CD39 Across Different Pathological Stages (CSG, CAG, LGIN, HGIN, and GC). (B) Quantitative Analysis of Positive Expression Areas of CD39. (C) Quantitative Analysis of Positive Expression Areas of B7-H3. (D) Representative Multiplex IHC Expression Patterns of B7-H3 and CD39 Across Different Pathological Stages (CSG, CAG, LGIN, HGIN, and GC). (E) Quantitative Analysis of Multiplex IHC Expression of B7-H3 and CD39. (F) Representative Co-Localization Expression of B7-H3 and CD39 in GC. IHC Scale Bars: 50 µm; mIHC Scale Bars: 100 µm.

Article Snippet: The following primary antibodies were used according to the manufacturer's instructions: mouse anti-human B7-H3 monoclonal antibody, 1/200 dilution (Cat No: 66 481-1-Ig, Proteintech, China), rabbit anti-human CD39 polyclonal antibody, 1/1000 dilution (Cat No: 14211-1-AP, Proteintech, China) and mouse anti-human CD8 monoclonal antibody, 1/10 000 dilution (Cat No: 66868-1-Ig, Proteintech, China).

Techniques: Expressing, Multiplex Assay

Co-Localization of B7-H3 and CD39 in Gastric Cancer Cells Indicates Poor Prognosis. (A, B) Representative Immunohistochemical Images Showing Low and High Expression of B7-H3 (A) and CD39 (B) in Gastric Cancer (GC) Specimens. (C) Correlation Analysis of B7-H3 and CD39 Expression. (F, G, H, I) Kaplan-Meier Survival Curves for Overall Survival of GC Patients Based on the Expression Status of B7-H3 (F), CD39 (G), Dual High Expression of B7-H3 and CD39 (H), and Co-Localized Expression Status of B7-H3-CD39 (I). Scale Bars: 100 µm.

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Co-Localization of B7-H3 and CD39 in Gastric Cancer Cells Indicates Poor Prognosis. (A, B) Representative Immunohistochemical Images Showing Low and High Expression of B7-H3 (A) and CD39 (B) in Gastric Cancer (GC) Specimens. (C) Correlation Analysis of B7-H3 and CD39 Expression. (F, G, H, I) Kaplan-Meier Survival Curves for Overall Survival of GC Patients Based on the Expression Status of B7-H3 (F), CD39 (G), Dual High Expression of B7-H3 and CD39 (H), and Co-Localized Expression Status of B7-H3-CD39 (I). Scale Bars: 100 µm.

Techniques: Immunohistochemical staining, Expressing

Absence of Correlation Between Co-localization of B7-H3 and CD39 Expression and CD8 + T Cell Infiltration in Gastric Cancer. (A, B) Representative Immunohistochemical Images Showing the Expression of B7-H3 with CD8 (A) or CD39 with CD8 (B) in the Same Patient. (C) Correlation Between B7-H3 Expression and CD8 Expression, and Between CD39 Expression and CD8 Expression. (D, E) Representative Multiplex Immunohistochemistry Images of B7-H3, CD39, and CD8 (D), and Correlation Analysis Between the Co-Localization Expression Score of B7-H3 and CD39 and the Extent of CD8 Infiltration (E). (F, G) Representative Multiplex Immunohistochemistry Images of CD39 and CD8, with Arrows Indicating CD39 + CD8 + T Cells (F), and the Proportion of CD39 + CD8 + T Cells within the CD8 + T Cell Population (G). Scale Bars: 100 µm.

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Absence of Correlation Between Co-localization of B7-H3 and CD39 Expression and CD8 + T Cell Infiltration in Gastric Cancer. (A, B) Representative Immunohistochemical Images Showing the Expression of B7-H3 with CD8 (A) or CD39 with CD8 (B) in the Same Patient. (C) Correlation Between B7-H3 Expression and CD8 Expression, and Between CD39 Expression and CD8 Expression. (D, E) Representative Multiplex Immunohistochemistry Images of B7-H3, CD39, and CD8 (D), and Correlation Analysis Between the Co-Localization Expression Score of B7-H3 and CD39 and the Extent of CD8 Infiltration (E). (F, G) Representative Multiplex Immunohistochemistry Images of CD39 and CD8, with Arrows Indicating CD39 + CD8 + T Cells (F), and the Proportion of CD39 + CD8 + T Cells within the CD8 + T Cell Population (G). Scale Bars: 100 µm.

Techniques: Expressing, Immunohistochemical staining, Multiplex Assay, Immunohistochemistry

Kaplan-Meier Survival Curves for Gastric Cancer Patients Based on Specific Expression Statuses and Immune Cell Infiltration Levels. (A, B, C, D) Kaplan-Meier Survival Curves for GC Patients Stratified by B7-H3 High CD8 Low (A) Expression Status 、 CD39 High CD8 Low (B) Expression Status 、 B7-H3-CD39 Both high CD8 Low Expression Status (C) and B7-H3-CD39 Co-localization CD8 low Expression Status (D). (E, F) Kaplan-Meier Survival Curves for GC Patients Based on CD8 + T Cell Infiltration Levels (E) and CD39 + CD8 + T Cell Infiltration Status (F).

Journal: Technology in Cancer Research & Treatment

Article Title: B7-H3 and CD39 Co-Localization in Gastric Cancer: A Potential Prognostic Biomarker and Potential Dual-Target for Immunotherapy

doi: 10.1177/15330338251380957

Figure Lengend Snippet: Kaplan-Meier Survival Curves for Gastric Cancer Patients Based on Specific Expression Statuses and Immune Cell Infiltration Levels. (A, B, C, D) Kaplan-Meier Survival Curves for GC Patients Stratified by B7-H3 High CD8 Low (A) Expression Status 、 CD39 High CD8 Low (B) Expression Status 、 B7-H3-CD39 Both high CD8 Low Expression Status (C) and B7-H3-CD39 Co-localization CD8 low Expression Status (D). (E, F) Kaplan-Meier Survival Curves for GC Patients Based on CD8 + T Cell Infiltration Levels (E) and CD39 + CD8 + T Cell Infiltration Status (F).

Techniques: Expressing

Increased ENTPD1 levels in lung, liver, spleen, and PBMCs from severe COVID-19 patients (A) Heatmaps representing the Treg gene set in lung, liver, and spleen of COVID-19 patients, compared with controls. Upregulated and downregulated genes are shown in red and blue. (B) Box plots showing the median ENTPD1 levels in biopsies from autoptic lung, heart, liver, kidney and spleen of COVID-19 patients (lung n = 5, liver n = 5, spleen n = 3) and controls (n = 2 for all organs). Results were obtained by NanoString. ∗p ≤ 0.05; ∗∗p ≤ 0.01 using two-sided unpaired t test. Samples were run in triplicate and experiments performed independently three times. (C) Expression of CD39 was tested in paraffin embedded sections obtained from biopsies of autoptic COVID-19 and control lung, heart, liver, kidney and spleen. Immunohistochemistry staining is shown from one COVID-19 patient and one control. Arrows indicate positively stained cells (magnification 20 x, scale bar 100 μM). A representative of three independent staining is shown. (D) ENTPD1 mRNA levels in PBMCs were determined by qPCR in moderate (n = 20), severe (n = 15), convalescent (n = 6) COVID-19 cases and in healthy controls (n = 6). Mean ± SEM is shown. ∗p ≤ 0.05, ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey’s multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. (E–H) Correlation between ENTPD1 mRNA levels and (E) D-Dimer, (F) prothrombin time (PT), length of stay in (G) hospital, and (H) intensive care unit (ICU) in moderate and severe patients. Coefficients associated with significant (p ≤ 0.05) correlations are indicated. See also <xref ref-type=

Figure S5 . " width="100%" height="100%">

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet: Increased ENTPD1 levels in lung, liver, spleen, and PBMCs from severe COVID-19 patients (A) Heatmaps representing the Treg gene set in lung, liver, and spleen of COVID-19 patients, compared with controls. Upregulated and downregulated genes are shown in red and blue. (B) Box plots showing the median ENTPD1 levels in biopsies from autoptic lung, heart, liver, kidney and spleen of COVID-19 patients (lung n = 5, liver n = 5, spleen n = 3) and controls (n = 2 for all organs). Results were obtained by NanoString. ∗p ≤ 0.05; ∗∗p ≤ 0.01 using two-sided unpaired t test. Samples were run in triplicate and experiments performed independently three times. (C) Expression of CD39 was tested in paraffin embedded sections obtained from biopsies of autoptic COVID-19 and control lung, heart, liver, kidney and spleen. Immunohistochemistry staining is shown from one COVID-19 patient and one control. Arrows indicate positively stained cells (magnification 20 x, scale bar 100 μM). A representative of three independent staining is shown. (D) ENTPD1 mRNA levels in PBMCs were determined by qPCR in moderate (n = 20), severe (n = 15), convalescent (n = 6) COVID-19 cases and in healthy controls (n = 6). Mean ± SEM is shown. ∗p ≤ 0.05, ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey’s multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. (E–H) Correlation between ENTPD1 mRNA levels and (E) D-Dimer, (F) prothrombin time (PT), length of stay in (G) hospital, and (H) intensive care unit (ICU) in moderate and severe patients. Coefficients associated with significant (p ≤ 0.05) correlations are indicated. See also Figure S5 .

Article Snippet: Sections were subsequently incubated overnight at 4°C with rabbit polyclonal anti-human CD39 (cat. # HPA014067, Sigma Aldrich) at 1/100 ( ).

Techniques: Expressing, Immunohistochemistry, Staining

ENTPD1 is aberrantly regulated in severe COVID-19 patients (A) Volcano plot showing down- and upregulated genes within the high ENTPD1 expressing group. High and low ENTPD1 expression was defined based on the median value (median ENTPD1 levels: 9.9, range: 9.43–10.77 obtained after pooling the ENTPD1 gene expression levels of severe and convalescent cases. nCounter CAR-T genes were then subdivided based on ENTPD1 levels and subsequently associated with high or low ENTPD1 expression. X and Y axes correspond to fold change and p value respectively. Downregulated and upregulated genes are shown in blue and red. The most significantly downregulated and upregulated genes are indicated. (B) Gene set enrichment analysis (GSEA) showing the gene pathways associated with high and low ENTPD1 expression levels (p value < 0.05 and false discovery rate q value < 0.05). High and low ENTPD1 expression was defined based on the median value obtained after pooling the ENTPD1 gene expression levels of severe and convalescent cases. nCounter CAR-T genes were then subdivided based on ENTPD1 levels and associated with high or low ENTPD1 expression. Lines represent individual gene sets. Upregulated genes are located on the left, while downregulated genes are located on the right of the plot. (C) PPI network between ENTPD1/CD39 and other protein-coding genes included in the nCounter CAR-T characterization panel was derived by STRING (threshold value of median confidence of 0.4). (D–F) Box plots showing the median (D) STAT-3 , (E) HIF-1α , and (F) AHR mRNA levels in PBMCs from moderate (n = 6), severe (n = 6) and convalescent (n = 6) COVID-19 patients and healthy controls (n = 6). Data were obtained by NanoString analysis. ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey's multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. (G) Levels of ENTPD1-AS RNA were tested by qPCR in moderate (n = 20), severe (n = 15), convalescent (n = 6) COVID-19 cases and in healthy controls (n = 6). Mean ± SEM ENTPD1-AS RNA is shown. ∗p ≤ 0.05, ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey’s multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. See also and .

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet: ENTPD1 is aberrantly regulated in severe COVID-19 patients (A) Volcano plot showing down- and upregulated genes within the high ENTPD1 expressing group. High and low ENTPD1 expression was defined based on the median value (median ENTPD1 levels: 9.9, range: 9.43–10.77 obtained after pooling the ENTPD1 gene expression levels of severe and convalescent cases. nCounter CAR-T genes were then subdivided based on ENTPD1 levels and subsequently associated with high or low ENTPD1 expression. X and Y axes correspond to fold change and p value respectively. Downregulated and upregulated genes are shown in blue and red. The most significantly downregulated and upregulated genes are indicated. (B) Gene set enrichment analysis (GSEA) showing the gene pathways associated with high and low ENTPD1 expression levels (p value < 0.05 and false discovery rate q value < 0.05). High and low ENTPD1 expression was defined based on the median value obtained after pooling the ENTPD1 gene expression levels of severe and convalescent cases. nCounter CAR-T genes were then subdivided based on ENTPD1 levels and associated with high or low ENTPD1 expression. Lines represent individual gene sets. Upregulated genes are located on the left, while downregulated genes are located on the right of the plot. (C) PPI network between ENTPD1/CD39 and other protein-coding genes included in the nCounter CAR-T characterization panel was derived by STRING (threshold value of median confidence of 0.4). (D–F) Box plots showing the median (D) STAT-3 , (E) HIF-1α , and (F) AHR mRNA levels in PBMCs from moderate (n = 6), severe (n = 6) and convalescent (n = 6) COVID-19 patients and healthy controls (n = 6). Data were obtained by NanoString analysis. ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey's multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. (G) Levels of ENTPD1-AS RNA were tested by qPCR in moderate (n = 20), severe (n = 15), convalescent (n = 6) COVID-19 cases and in healthy controls (n = 6). Mean ± SEM ENTPD1-AS RNA is shown. ∗p ≤ 0.05, ∗∗p ≤ 0.01 and ∗∗∗p ≤ 0.001 using one-way ANOVA followed by Tukey’s multiple comparisons test. Samples were run in triplicate and experiments performed independently three times. See also and .

Article Snippet: Sections were subsequently incubated overnight at 4°C with rabbit polyclonal anti-human CD39 (cat. # HPA014067, Sigma Aldrich) at 1/100 ( ).

Techniques: Expressing, Derivative Assay

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet:

Article Snippet: Sections were subsequently incubated overnight at 4°C with rabbit polyclonal anti-human CD39 (cat. # HPA014067, Sigma Aldrich) at 1/100 ( ).

Techniques: Plasmid Preparation, Software

Figure S5 . " width="100%" height="100%">

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Article Snippet: Rabbit polyclonal anti-human CD39 , Sigma Aldrich , Cat. # HPA014067; RRID: AB_1848178.

Techniques: Expressing, Immunohistochemistry, Staining

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Article Snippet: Rabbit polyclonal anti-human CD39 , Sigma Aldrich , Cat. # HPA014067; RRID: AB_1848178.

Techniques: Expressing, Derivative Assay

Journal: iScience

Article Title: Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19

doi: 10.1016/j.isci.2021.103205

Figure Lengend Snippet:

Article Snippet: Rabbit polyclonal anti-human CD39 , Sigma Aldrich , Cat. # HPA014067; RRID: AB_1848178.

Techniques: Plasmid Preparation, Software

Review

anti human cd39 polyclonal antibody (Proteintech)

Structured Review

Images

1) Product Images from "Clonotype-Resolved Single-Cell Multi-Omics Unlocks the Profile of Tumor-Infiltrating CD39⁺CD8⁺ T Cells and Enables Adoptive Cell Therapy for Solid Tumor"

Related Articles

Immunohistochemistry:

Staining:

Similar Products

Image Search Results